SCHEMBL481360

SCHEMBL481360

c1ccc2c3c([nH]c2c1)CCC3

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.68
ALDH1A1 P00352 1/20 0.68
HTR2A P28223 1/20 0.67
HTR2C P28335 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.66
NR2E1 Q9Y466 2/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
HSD17B10 Q99714 1/20 0.59
HTR5A P47898 1/20 0.59
NISCH Q9Y2I1 1/20 0.59
TAAR1 Q96RJ0 1/20 0.58
MAPT P10636 1/20 0.58
PARP1 P09874 1/20 0.56
CHRNA7 P36544 1/20 0.54
DRD2 P14416 1/20 0.53
DRD1 P21728 1/20 0.53
DRD4 P21917 1/20 0.53
DRD5 P21918 1/20 0.53
DRD3 P35462 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29936982 1.00 KDM4E (0.68) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
SCHEMBL104598 0.96 KDM4E (0.73) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
SCHEMBL30160092 0.96 KDM4E (0.73) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
SCHEMBL11641810 0.94 SMN1; SMN2 (0.74) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
Bromide SCHEMBL8568783 0.94 KDM4E (0.71) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
Iodide SCHEMBL8569085 0.94 KDM4E (0.71) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
SCHEMBL30657796 0.94 SMN1; SMN2 (0.74) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
SCHEMBL7402531 0.94 KDM4E (0.71) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
SCHEMBL14156164 0.94 SMN1; SMN2 (0.74) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2
SCHEMBL15266076 0.94 KDM4E (0.71) KDM4EALDH1A1HTR2AHTR2CSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4334367-A None JP disclosed
WO-2025121418-A1 HEPATITIS C VIRUS INHIBITOR 国立大学法人浜松医科大学 2025-06-12 WO disclosed
WO-2024233280-A1 HETEROBIFUNCTIONAL SMALL MOLECULES THAT DEUBIQUITINYLATE AND STABILIZE TARGET PROTEINS BY RECRUITING USP7 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-11-14 WO disclosed
US-12138243-B2 Antiviral use of FABP4 modulating compounds CRESCENTA BIOSCIENCES (US) 2024-11-12 US disclosed
US-12084419-B2 Cell metabolism modulating compounds and uses thereof CRESCENTA BIOSCIENCES (US) 2024-09-10 US disclosed
US-20240268230-A1 LIGHT EMITTING ELEMENT AND FUSED POLYCYCLIC COMPOUND FOR THE LIGHT EMITTING ELEMENT SAMSUNG DISPLAY CO., LTD. (KR) 2024-08-08 US disclosed
CN-118290453-A Light-emitting element and condensed polycyclic compound for light-emitting element 三星显示有限公司 2024-07-05 CN disclosed
US-20240180882-A1 COMPOUNDS FOR PROTECTION OF NOISE-INDUCED HEARING-LOSS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-06 US disclosed
WO-2023189803-A1 RESIST UNDERLAYER FILM FORMING COMPOSITION 日産化学株式会社 2023-10-05 WO disclosed
US-20230272401-A1 COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF Genetic Intelligence, Inc 2023-08-31 US disclosed
JP-H04334367-A SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENT(B)INDOLE, 1,2,3,3A,4,8A-HEXAHYDROCYCLOPENT(B)INDOLE AND RELATED COMPOUND HOECHST ROUSSEL PHARMACEUT INC 1992-11-20 JP disclosed
EP-0496314-A1 Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[b]indoles and related compounds, intermediates and a process for the preparation thereof and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1992-07-29 EP disclosed
US-5100891-A Antidepressants HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1992-03-31 US disclosed
US-4319029-A DIURETICS, ANTIMETABOLIC AGENTS, HYPOTENSIVE AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1982-03-09 US disclosed
US-4319029-A DIURETICS, ANTIMETABOLIC AGENTS, HYPOTENSIVE AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1982-03-09 US disclosed
EP-0033797-A1 1-Hydroxyalkanamine tetrahydrocarbazoles, their preparation, pharmaceutical compositions containing same and their preparation, intermediates therefor and their preparation AMERICAN HOME PRODUCTS CORPORATION (US) 1981-08-19 EP disclosed
US-4235903-A DIURETICS, MINERALCORTICOID ACTIVITY, HYPERTENSIVE AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1980-11-25 US disclosed
US-4235903-A DIURETICS, MINERALCORTICOID ACTIVITY, HYPERTENSIVE AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1980-11-25 US disclosed
US-4128560-A Tricyclic alkylamine derivatives AYERST MCKENNA & HARRISON LTD. (CA) 1978-12-05 US disclosed
US-4128560-A Tricyclic alkylamine derivatives AYERST MCKENNA & HARRISON LTD. (CA) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12084419-B2 Cell metabolism modulating compounds and uses thereof FABP4, FABP1, FABP3 KDM4E 2023/4885ALDH1A1 982/4885HTR2A 3308/4885
US-20230272401-A1 COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF TARDBP, FUS, RBM17 KDM4E 2645/4885ALDH1A1 4065/4885HTR2A 4451/4885
US-12138243-B2 Antiviral use of FABP4 modulating compounds FABP1, FABP5, FABP4 KDM4E 1620/4885ALDH1A1 2077/4885HTR2A 3578/4885
US-20240268230-A1 LIGHT EMITTING ELEMENT AND FUSED POLYCYCLIC COMPOUND FOR THE LIGHT EMITTING ELEMENT LAGE3, NR2E3, NBAS KDM4E 1707/4885ALDH1A1 515/4885HTR2A 2096/4885
US-20240180882-A1 COMPOUNDS FOR PROTECTION OF NOISE-INDUCED HEARING-LOSS PRKAG1, PRKAG3, PRKAG2 KDM4E 2502/4885ALDH1A1 1245/4885HTR2A 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.